Innovation in bone healing and tissue repair

CYT003

Arbutus (formally known as Oncore)
In January 2015 Cytos has exclusively licensed CYT003 in the field of Hepatitis B to Arbutus Pharmaceuticals LLC.

Checkmate Pharmaceuticals LLC
In August 2015 Cytos has exclusively licensed CYT003 in the field of Oncology to Checkmate Pharmaceuticals LLC.

 

VLP platform

Pfizer

Pfizer is developing a novel anti-IgE vaccine based on Cytos' Qb VLP platform under an exclusive commercial license agreement with Cytos. A Phase 1 clinical trial with the anti-IgE vaccine began in 2013 and was completed in June 2015.

Singapore Government

In July 2010, Cytos and Singapore’s Agency for Science, Technology and Research (A*STAR) established a Collaborative Research, Development and Commercialization Agreement for the research, development and commercialization of an influenza vaccine. A Phase 1 clinical trial with the H1N1 influenza vaccine candidate based on Cytos’ proprietary bacteriophage Qbeta virus-like particle (VLP) technology was conducted in 2013. In this first Phase 1 clinical trial, the safety and immunogenicity of this novel vaccine candidate and its potential to protect against H1N1 influenza infection was evaluated.

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Collaborations

CYT003

Arbutus (formally known as Oncore)
In January 2015 Cytos has exclusively licensed CYT003 in the field of Hepatitis B to Arbutus Pharmaceuticals LLC.

Checkmate Pharmaceuticals LLC
In August 2015 Cytos has exclusively licensed CYT003 in the field of Oncology to Checkmate Pharmaceuticals LLC.

 

VLP platform

Pfizer

Pfizer is developing a novel anti-IgE vaccine based on Cytos' Qb VLP platform under an exclusive commercial license agreement with Cytos. A Phase 1 clinical trial with the anti-IgE vaccine began in 2013 and was completed in June 2015.

Singapore Government

In July 2010, Cytos and Singapore’s Agency for Science, Technology and Research (A*STAR) established a Collaborative Research, Development and Commercialization Agreement for the research, development and commercialization of an influenza vaccine. A Phase 1 clinical trial with the H1N1 influenza vaccine candidate based on Cytos’ proprietary bacteriophage Qbeta virus-like particle (VLP) technology was conducted in 2013. In this first Phase 1 clinical trial, the safety and immunogenicity of this novel vaccine candidate and its potential to protect against H1N1 influenza infection was evaluated.